^
    1year
    2/ @LeXiuning @MDAndersonNews on EGFR mutations: ▪️EGFR mutations ~10-20% NSCLC pts in Europe/N America, & up to 50% of patients in Asia ▪️Exon 19 del & exon 21 L858R most common (~85-90%) ▪️🔑 Most frequent uncommon mutations to know: G719X, S768I, L861Q, & exon 20 insertions (@esinghimd)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    over1year
    Rare mutation question. What would be your front line choice for metastatic NSCLC adeno with EGFR S768I? #Lcsm @EGFRSummit @EGFRResisters @christine_lovly @AparGanti @CharuAggarwalMD @JackWestMD @dipeshuprety4 @HemOncWomenDocs (@DevikaDasMD)
    EGFR (Epidermal growth factor receptor)
    |
    EGFR S768I
    almost2years
    I completely echo @DrSanjayPopat (tweet ⬆️)“Would suggest nil more,on t basis of data-everything else is conjecture. @myESMO EGFR expert consensus states “with…S768I in combo with non-common alterations, the use of osi cannot be recommended based on current efficacy data” #LCSM (@APassaroMD)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR S768I
    over2years
    For unresectable stage III NSCLC s/p chemo RT and a NGS revealing EGFR S768I ( or similar) would you? #lcsm @JackWestMD @PatelOncology @CharuAggarwalMD @LeciaSequist @HornLeora @benlevylungdoc @DrSteveMartin @BrunaPellini (@DevikaDasMD)
    Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR S768I
    almost3years
    Need help with a #lungcancer patient 66 y/o F , non smoker Stage4- pleural effusion adenoca 2 EGFR mutations EXON 20 c.2303G>T (p.S768I) Exon 21: c.2573T>G (p.L858R) Tx options? Tagrisso? @PatelOncology @JackWestMD @HosseinBorghaei (@BijoyTelivala)
    Clinical • Pleural effusion
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR S768I
    |
    Tagrisso (osimertinib)